中國醫療集團(08225.HK):喜恩卡片劑和重酒石酸卡巴拉汀原料藥獲GMP生產批准
格隆匯6月8日丨中國醫療集團(08225.HK)發佈公告,公司負責的臨牀研究開發服務喜恩卡片劑(重酒石酸卡巴拉汀片劑)和重酒石酸卡巴拉汀原料藥在今年獲得新藥批准後在2020年6月5日獲得GMP生產批准,其中喜恩卡片是全球第一個上市的獨家片劑,國內第一家獲得該產品的生產證書,據悉另外兩家國產仿製膠囊尚未上市銷售。
集團將負責包括喜恩卡、優芝青在內利用RWS-THERAPY和CRCO平台開展上市後真實世界臨牀研究,服務專家在研究中精準治療患者,在治療中獲取研究成果,幫助企業開展數位化學術推廣。集團管理層相信這將對集團收入產生積極影響。
集團喜恩抗痴呆臨牀研究組,在阿茲海默疾病研究中參與了包括多奈呱齊、美金剛、卡巴拉汀和中藥等該領域80%產品的臨牀研究構築豐富經驗和競爭力。
腦科學將是繼腫瘤後的更大領域。公司的喜恩腦科數位臨牀研究中心,長期致力於卒中、痴呆、癲癇、帕金森和漸凍症等腦科臨牀和大資料研究,參與或組織了60%以上國家腦科學重大臨牀研究,其中部分專案還獲得了國家科學進步一二等獎。
集團在海南省佈局的三家醫療公司將會享受國務院最近賦予海南的税務醫院合作和臨牀研究的特惠政策,集團管理層相信集團在海南的10多年努力業績將會受政策積極影響而快速提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.